Solstice Capital

Regenesis Biomedical Inc. is a medical device company based in Scottsdale, Arizona, founded in 1996. The company specializes in the research, design, manufacture, and sale of noninvasive regenerative medicine products aimed at alleviating pain and restoring health. Its primary product, the Provant Therapy System, utilizes an electromagnetic field to reduce pain and swelling in skin and soft tissues following surgical procedures. The company serves a diverse clientele that includes healthcare facilities, acute and long-term care hospitals, skilled nursing facilities, rehabilitation centers, outpatient clinics, and home healthcare providers, all catering to patients under physician orders. Through its innovative approach, Regenesis Biomedical strives to enhance the quality of life for patients experiencing post-operative discomfort.

HTG Molecular Diagnostics is a commercial stage life sciences company based in Tucson, Arizona, specializing in precision medicine. The company develops and markets molecular-based technology solutions for gene expression profiling and the measurement of miRNA, siRNA, and mRNA, which are essential for translational medicine and diagnostic applications. HTG offers a range of instrumentation, assay kits, and software that automate sample processing and analyze various molecular targets. Its platforms create molecular profiling libraries for next-generation sequencing, with marketed panels including oncology biomarker panels and immuno-oncology assays. HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, distributing its products directly within the United States and Europe, as well as through distributors in other regions. The company is also engaged in collaborations for the development of RNA and DNA profiling tests, enhancing its role in the evolving landscape of molecular diagnostics.

HTG Molecular Diagnostics is a commercial stage life sciences company based in Tucson, Arizona, specializing in precision medicine. The company develops and markets molecular-based technology solutions for gene expression profiling and the measurement of miRNA, siRNA, and mRNA, which are essential for translational medicine and diagnostic applications. HTG offers a range of instrumentation, assay kits, and software that automate sample processing and analyze various molecular targets. Its platforms create molecular profiling libraries for next-generation sequencing, with marketed panels including oncology biomarker panels and immuno-oncology assays. HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, distributing its products directly within the United States and Europe, as well as through distributors in other regions. The company is also engaged in collaborations for the development of RNA and DNA profiling tests, enhancing its role in the evolving landscape of molecular diagnostics.

Regenesis Biomedical Inc. is a medical device company based in Scottsdale, Arizona, founded in 1996. The company specializes in the research, design, manufacture, and sale of noninvasive regenerative medicine products aimed at alleviating pain and restoring health. Its primary product, the Provant Therapy System, utilizes an electromagnetic field to reduce pain and swelling in skin and soft tissues following surgical procedures. The company serves a diverse clientele that includes healthcare facilities, acute and long-term care hospitals, skilled nursing facilities, rehabilitation centers, outpatient clinics, and home healthcare providers, all catering to patients under physician orders. Through its innovative approach, Regenesis Biomedical strives to enhance the quality of life for patients experiencing post-operative discomfort.

AmpliMed Corporation focuses on the development of small-molecule oncology drugs. Its products include Amplimexon, a small molecule that causes cancer cells to stop dividing and ultimately to die; Amplizone that has demonstrated efficacy in the treatment of solid tumors in animal tumor models; and benzimidazole Series: benzimidazole analog small molecules that expressed tubulin binding activity in yeast and mammalian cells. The company’s products are used to treat pancreatic cancer, lung cancer, malignant melanoma, ovarian cancer, and multiple myeloma. AmpliMed Corporation was founded in 1989 and is based in Tucson, Arizona.

HTG Molecular Diagnostics is a commercial stage life sciences company based in Tucson, Arizona, specializing in precision medicine. The company develops and markets molecular-based technology solutions for gene expression profiling and the measurement of miRNA, siRNA, and mRNA, which are essential for translational medicine and diagnostic applications. HTG offers a range of instrumentation, assay kits, and software that automate sample processing and analyze various molecular targets. Its platforms create molecular profiling libraries for next-generation sequencing, with marketed panels including oncology biomarker panels and immuno-oncology assays. HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, distributing its products directly within the United States and Europe, as well as through distributors in other regions. The company is also engaged in collaborations for the development of RNA and DNA profiling tests, enhancing its role in the evolving landscape of molecular diagnostics.

Regenesis Biomedical Inc. is a medical device company based in Scottsdale, Arizona, founded in 1996. The company specializes in the research, design, manufacture, and sale of noninvasive regenerative medicine products aimed at alleviating pain and restoring health. Its primary product, the Provant Therapy System, utilizes an electromagnetic field to reduce pain and swelling in skin and soft tissues following surgical procedures. The company serves a diverse clientele that includes healthcare facilities, acute and long-term care hospitals, skilled nursing facilities, rehabilitation centers, outpatient clinics, and home healthcare providers, all catering to patients under physician orders. Through its innovative approach, Regenesis Biomedical strives to enhance the quality of life for patients experiencing post-operative discomfort.

Carefx is a provider of information technology solutions specifically designed for healthcare organizations in North America and Europe. The company's primary offering, Fusionfx, is an interoperable workflow and analytics solution that addresses information gaps between healthcare executives and IT departments. By synthesizing disparate data into clinically relevant, user-centric workflows, Fusionfx connects care providers with essential information, enhancing both clinical and business operations. Additionally, the solution includes business intelligence dashboards that promote accountability and transparency within healthcare organizations, thereby improving the overall efficiency and effectiveness of patient care.

HTG Molecular Diagnostics is a commercial stage life sciences company based in Tucson, Arizona, specializing in precision medicine. The company develops and markets molecular-based technology solutions for gene expression profiling and the measurement of miRNA, siRNA, and mRNA, which are essential for translational medicine and diagnostic applications. HTG offers a range of instrumentation, assay kits, and software that automate sample processing and analyze various molecular targets. Its platforms create molecular profiling libraries for next-generation sequencing, with marketed panels including oncology biomarker panels and immuno-oncology assays. HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, distributing its products directly within the United States and Europe, as well as through distributors in other regions. The company is also engaged in collaborations for the development of RNA and DNA profiling tests, enhancing its role in the evolving landscape of molecular diagnostics.

Carefx is a provider of information technology solutions specifically designed for healthcare organizations in North America and Europe. The company's primary offering, Fusionfx, is an interoperable workflow and analytics solution that addresses information gaps between healthcare executives and IT departments. By synthesizing disparate data into clinically relevant, user-centric workflows, Fusionfx connects care providers with essential information, enhancing both clinical and business operations. Additionally, the solution includes business intelligence dashboards that promote accountability and transparency within healthcare organizations, thereby improving the overall efficiency and effectiveness of patient care.

AmpliMed Corporation focuses on the development of small-molecule oncology drugs. Its products include Amplimexon, a small molecule that causes cancer cells to stop dividing and ultimately to die; Amplizone that has demonstrated efficacy in the treatment of solid tumors in animal tumor models; and benzimidazole Series: benzimidazole analog small molecules that expressed tubulin binding activity in yeast and mammalian cells. The company’s products are used to treat pancreatic cancer, lung cancer, malignant melanoma, ovarian cancer, and multiple myeloma. AmpliMed Corporation was founded in 1989 and is based in Tucson, Arizona.

AmpliMed Corporation focuses on the development of small-molecule oncology drugs. Its products include Amplimexon, a small molecule that causes cancer cells to stop dividing and ultimately to die; Amplizone that has demonstrated efficacy in the treatment of solid tumors in animal tumor models; and benzimidazole Series: benzimidazole analog small molecules that expressed tubulin binding activity in yeast and mammalian cells. The company’s products are used to treat pancreatic cancer, lung cancer, malignant melanoma, ovarian cancer, and multiple myeloma. AmpliMed Corporation was founded in 1989 and is based in Tucson, Arizona.

HTG Molecular Diagnostics is a commercial stage life sciences company based in Tucson, Arizona, specializing in precision medicine. The company develops and markets molecular-based technology solutions for gene expression profiling and the measurement of miRNA, siRNA, and mRNA, which are essential for translational medicine and diagnostic applications. HTG offers a range of instrumentation, assay kits, and software that automate sample processing and analyze various molecular targets. Its platforms create molecular profiling libraries for next-generation sequencing, with marketed panels including oncology biomarker panels and immuno-oncology assays. HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, distributing its products directly within the United States and Europe, as well as through distributors in other regions. The company is also engaged in collaborations for the development of RNA and DNA profiling tests, enhancing its role in the evolving landscape of molecular diagnostics.

AmpliMed Corporation focuses on the development of small-molecule oncology drugs. Its products include Amplimexon, a small molecule that causes cancer cells to stop dividing and ultimately to die; Amplizone that has demonstrated efficacy in the treatment of solid tumors in animal tumor models; and benzimidazole Series: benzimidazole analog small molecules that expressed tubulin binding activity in yeast and mammalian cells. The company’s products are used to treat pancreatic cancer, lung cancer, malignant melanoma, ovarian cancer, and multiple myeloma. AmpliMed Corporation was founded in 1989 and is based in Tucson, Arizona.

Carefx is a provider of information technology solutions specifically designed for healthcare organizations in North America and Europe. The company's primary offering, Fusionfx, is an interoperable workflow and analytics solution that addresses information gaps between healthcare executives and IT departments. By synthesizing disparate data into clinically relevant, user-centric workflows, Fusionfx connects care providers with essential information, enhancing both clinical and business operations. Additionally, the solution includes business intelligence dashboards that promote accountability and transparency within healthcare organizations, thereby improving the overall efficiency and effectiveness of patient care.

HTG Molecular Diagnostics is a commercial stage life sciences company based in Tucson, Arizona, specializing in precision medicine. The company develops and markets molecular-based technology solutions for gene expression profiling and the measurement of miRNA, siRNA, and mRNA, which are essential for translational medicine and diagnostic applications. HTG offers a range of instrumentation, assay kits, and software that automate sample processing and analyze various molecular targets. Its platforms create molecular profiling libraries for next-generation sequencing, with marketed panels including oncology biomarker panels and immuno-oncology assays. HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, distributing its products directly within the United States and Europe, as well as through distributors in other regions. The company is also engaged in collaborations for the development of RNA and DNA profiling tests, enhancing its role in the evolving landscape of molecular diagnostics.

Sequencia offers a web-based, collaborative Product Lifecycle Management (PLM) solution known as processPoint, tailored for industries such as consumer packaged goods, food and beverage, pharmaceuticals, and specialty chemicals. In addition to its PLM capabilities, Sequencia provides supply chain management services and has developed an enterprise resource planning platform that enhances vendor management. This integrated approach supports businesses in efficiently managing their product development and supply chain processes.